The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its significance h...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015, Vol.10 (7), p.e0132821-e0132821
Main Authors: Czarniecka, Agnieszka, Kowal, Monika, Rusinek, Dagmara, Krajewska, Jolanta, Jarzab, Michal, Stobiecka, Ewa, Chmielik, Ewa, Zembala-Nozynska, Ewa, Poltorak, Stanislaw, Sacher, Aleksander, Maciejewski, Adam, Zebracka-Gala, Jadwiga, Lange, Dariusz, Oczko-Wojciechowska, Malgorzata, Handkiewicz-Junak, Daria, Jarzab, Barbara
Format: Article
Language:English
Subjects:
Adult
Amino Acid Substitution
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Cancer therapies
Carcinoma - diagnosis
Carcinoma - genetics
Carcinoma - mortality
Carcinoma - pathology
Carcinoma, Papillary
Clinical trials
Dissection
Feasibility studies
Female
Gene Frequency
Glutamic Acid - genetics
Health risks
Humans
Lymph
Lymph nodes
Lymphatic system
Male
Medical diagnosis
Medical prognosis
Metastases
Metastasis
Middle Aged
Mutation
Mutation, Missense
Nuclear medicine
Oncology
Papillary thyroid cancer
Pathology
Patients
Plastic surgery
Predictive Value of Tests
Prognosis
Proto-Oncogene Proteins B-raf - genetics
Recurrence
Risk Factors
Thyroid
Thyroid cancer
Thyroid Cancer, Papillary
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - genetics
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
Tumors
Valine - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its significance has been proved by retrospective analyses, involving a large group of patients. The question arises whether this factor is useful in smaller populations, characterised for specialised centres. Thus, the aim of the study was to evaluate the use of BRAF mutation as a potential predictive marker in PTC patients. 233 PTC subjects treated between 2004-2006, were retrospectively analysed. Stage pT1 was diagnosed in 64.8% patients and lymph node metastases in 30.9%. Median follow-up was 7.5 years. BRAFV600E mutation was assessed postoperatively in all cases. BRAF V600E mutation was found in 54.5%. It was more frequent in patients > 45 years (p=0.0001), and associated with larger tumour size (p=0.004). Patients with tumours
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0132821